Jun 27 |
Oncolytics Biotech UP 1.9% In US Premarket Announces "Productive" FDA Type C Meeting on Metastatic Breast Cancer Program
|
Jun 27 |
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
|
Jun 24 |
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence
|
Jun 21 |
Oncolytics doses first subject in pancreatic cancer trial
|
Jun 20 |
Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
|
Jun 4 |
Oncolytics Biotech (ONCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
|
May 24 |
Oncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic Cancer
|
May 24 |
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action
|
May 16 |
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
|
May 15 |
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
|